Schedule a COVID vaccine or booster appointment:
Log in to myPennMedicine or call us 8am to 5pm, Monday through Friday, at 267-758-4902.
Not accepting new patients
Recognized by Best Doctors in America 2003 - 2018
Perelman Center for Advanced Medicine
West Pavilion, 2nd Floor
3400 Civic Center Boulevard
Philadelphia, PA 19104
A facility of the Hospital of the University of Pennsylvania
The Patient Satisfaction Rating is an average of all responses to the care provider related question shown above from our internal platform, PMX Feedback. Responses are measured on a scale of 1 to 5 with 5 being the best score. Scores reflect either the most recent 12 months of surveys or the most recent 30 surveys overall. Data is updated monthly and comments remain on the profile for 12 months.
Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.
Patients that are treated in outpatient or hospital environments may receive different surveys.
Shirao K, Hoff PM, Ohtsu A, Loehrer PJ, Hyodo I, Wadler S, Wadleigh RG, O’Dwyer PJ, Muro K, Yamada Y, Boku N, Nagashima F, Abbruzzese JL: Comparison between the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur plus oral leucovorin regimen in Japanese and American patients with advanced colorectal cancer: joint USA and Japan study of UFT/LV : 2003.
Flaherty KT, Stevenson JP, Hahn SM, Redlinger M, O’Dwyer PJ: Dose escalation and safety study of gemcitabine, carboplatin, and paclitaxel in patients with adavanced malignancy Cancer Chemother Pharmacol : 2003.
Giantonio BJ, Derry C, McAleer C, McPhillips JJ, O’Dwyer PJ: Phase I and pharmacokinetic study of the cytotoxic ether lipid ilmofosine administered by weekly 2-hour infusion in patients with advanced solid tumors : 2003.
Yao KS, O’Dwyer PJ: Role of the AP-1 element in mediating transcriptional induction of DT-diaphorase gene expression by oltipraz: a target for chemoprevention Biochem Pharmacol : 2003.
Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M, Wang YC, Duran GE, Sikic TL, Caldeira S, Skomedal H, Tu I-P, Hernandez-Boussard T, Johnson SW, O’Dwyer PJ, Fero M, Kristensen GB, Borresen-Dale A-L, Hastie T, Tibshirani R, van de Rijn M, Teng NN, Longacre TA, Botstein D, Brown PO, Sikic BI: Gene expression patterns in epithelial ovarian carcinomas : 2003.
Flaherty KT, O'Dwyer PJ: Phase II trials in oncology Anticancer Drug Development Guide : 2003.
Vasilevskaya I, O’Dwyer PJ: Role of Jun and Jun kinase (JNK) in resistance of cancer cells to therapy Drug Resistance Updates : 2003.
O’Dwyer PJ, Johnson SW: Current status of oxaliplatin in colorectal cancer Semin Oncol 30 (3 Supp 6): 78-87,2003.
Bilenker JH, Stevenson JP, Flaherty KT, Algazy K, McLaughlin K, Haller DG, Giantonio BJ, Garcia-Vargas JE, O’Dwyer PJ: Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies : 2003.
Veronese ML, Stevenson JP, Sun W, Redlinger M, Algazy K, Giantonio BJ, Hahn S, Vaughn D, Haller DG, O’Dwyer PJ: Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer : 2003.
Division of Hematology Oncology Perelman Center for Advanced Medicine 10th Floor, South PavilionOffice #10-3013400 Civic Center Blvd
Patient appointments: 800-789-7366